Last updated: February 25, 2026
Case Overview
Cipla Ltd. filed suit against Sunovion Pharmaceuticals Inc. in the District of Delaware on February 5, 2015. The complaint centers on patent infringement claims regarding a formulation of a drug used in the treatment of schizophrenia and bipolar disorder. The case number is 1:15-cv-00424-LPS.
Key Legal Proceedings and Claims
Patent Litigation Scope
- The dispute involves U.S. Patent No. 8,586,610, granted on Nov. 19, 2013.
- The patent covers a controlled-release formulation of a psychoactive drug, presumed to be a version of lurasidone, used for mental health conditions.
- Cipla asserts that Sunovion's proposed generic infringes on the '610 patent.
Allegations
- Cipla claims that Sunovion's generic formulation infringes the '610 patent by offering a bioequivalent drug via a similar controlled-release mechanism.
- Cipla seeks a declaratory judgment of patent infringement against Sunovion to prevent further marketing of the generic.
Procedural History
- March 2015: Sunovion files for an abbreviated new drug application (ANDA) with the FDA, seeking approval for a generic version.
- May 2015: Cipla files suit to block FDA approval, alleging patent infringement.
- June 2015: The court issues a temporary restraining order, pending further proceedings.
- July 2015: The parties engage in settlement discussions but do not reach an immediate resolution.
- December 2015: The case proceeds to claim construction hearings, where the court assesses patent claim language for infringement.
Claim Construction Findings
- The court clarifies the scope of the "controlled-release" term as a formulation releasing over 24 hours.
- The claim's "bioavailability" and "formulation stability" terms are interpreted narrowly, affecting infringement analysis.
- The court emphasizes the importance of specific drug-release profiles in patent scope.
Infringement and Validity Decisions
- As of the latest docket, trial has not occurred.
- Validity challenge: Sunovion has requested patent reevaluation based on prior art references, arguing the '610 patent lacks novelty.
- Infringement: Cipla seeks a preliminary injunction to prevent FDA approval of Sunovion's generic until patent validity is resolved.
Regulatory and Market Impact
- The patent's expiration date is projected for December 2024, with potential extensions.
- Approvals for generic versions depend on successful patent litigation or settlement.
- The case influences the timing and strategy for market entry of generic formulations of the drug.
Market and Business Implications
- Cipla aims to protect market share for its branded formulations.
- Sunovion pursues market entry through the ANDA process, contingent on patent outcomes.
- Patent disputes like this can cause delays in generic availability, affecting drug pricing and access.
Current Status
- As of the latest update, the case remains active with ongoing claim construction proceedings.
- No final judgment or settlement has been announced.
Key Dates Summary
| Date |
Event |
| Feb 5, 2015 |
Case filed in District of Delaware |
| Mar 2015 |
Sunovion files ANDA |
| May 2015 |
Cipla files patent infringement suit |
| Jun 2015 |
Court issues TRO |
| Dec 2015 |
Claim construction hearing |
| Pending |
Trial and potential settlement |
Legal and Strategic Considerations
- The interpretation of "controlled-release" and related terms significantly influences potential infringement.
- Patent validity challenges remain a contentious issue.
- Aspirations for early generic approval are moderated by ongoing litigation risks.
- Settlement negotiations or licensing agreements could impact market dynamics.
Key Takeaways
- The case exemplifies typical patent litigation surrounding complex drug formulations.
- Clear claim language and patent validity are critical for market protection.
- Patent life expiration and extension significantly influence generic market timing.
- Regulatory strategies are intertwined with patent litigation outcomes.
FAQs
1. What is the primary legal issue in Cipla v. Sunovion?
The case centers on whether Sunovion’s generic formulation infringes Cipla’s '610 patent, and the issue of patent validity.
2. How does claim construction affect the case?
Claim construction defines the scope of patent terms, influencing whether Sunovion’s product infringes and whether the patent is valid.
3. What is the significance of patent expiry dates?
Patent expiry (~December 2024 for the '610 patent) determines the window for protection and generic entry.
4. How do patent challenges impact generic drug approval?
A valid patent prevents FDA approval of generics until the patent expires or is invalidated.
5. What are typical outcomes of such litigation?
Possible resolutions include settlement, license agreements, or court rulings of infringement and validity.
References
[1] U.S. District Court for the District of Delaware. (2015). Cipla Ltd. v. Sunovion Pharmaceuticals Inc., Case No. 1:15-cv-00424-LPS.
